AIM ImmunoTech Inc. — Director's Dealing 2020

Jan 2, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AIM ImmunoTech Inc. (AIM)
CIK: 0000946644
Period of Report: 2019-12-31

Reporting Person: EQUELS THOMAS K. (Director, Exec.Vice Chairman/CEO/Pres.)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-12-31	Common Stock	A	14741	$0.53	Acquired	160990	Direct

Footnotes

F1: Common Stock Award. Vests in six months, provided continuous employment.